Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Rating of “Moderate Buy” from Brokerages

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has earned an average rating of “Moderate Buy” from the five ratings firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $44.00.

A number of research firms have recently issued reports on INO. Royal Bank of Canada reduced their price target on shares of Inovio Pharmaceuticals from $11.00 to $8.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th. Stephens started coverage on Inovio Pharmaceuticals in a report on Tuesday, May 14th. They set an “overweight” rating and a $20.00 price objective for the company. Oppenheimer decreased their target price on Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, August 12th. Finally, HC Wainwright restated a “neutral” rating and issued a $15.00 price target on shares of Inovio Pharmaceuticals in a research report on Monday, July 15th.

Inovio Pharmaceuticals Trading Up 2.1 %

NASDAQ:INO opened at $6.41 on Tuesday. Inovio Pharmaceuticals has a 1 year low of $3.89 and a 1 year high of $14.75. The stock has a fifty day moving average price of $8.81 and a two-hundred day moving average price of $9.92.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.09). The company had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.10 million. Inovio Pharmaceuticals had a negative net margin of 16,238.91% and a negative return on equity of 99.51%. During the same quarter in the prior year, the business earned ($1.56) EPS. Equities analysts anticipate that Inovio Pharmaceuticals will post -4.54 earnings per share for the current year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company purchased a new position in Inovio Pharmaceuticals in the 2nd quarter valued at about $82,000. Dimensional Fund Advisors LP purchased a new position in shares of Inovio Pharmaceuticals during the second quarter valued at approximately $605,000. Cornercap Investment Counsel Inc. acquired a new stake in Inovio Pharmaceuticals during the second quarter worth approximately $184,000. American Century Companies Inc. grew its stake in Inovio Pharmaceuticals by 62.2% in the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock worth $255,000 after acquiring an additional 12,100 shares during the period. Finally, Rhumbline Advisers grew its stake in Inovio Pharmaceuticals by 5,943.0% in the 2nd quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 37,857 shares during the period. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.